Once-weekly liposomal amphotericin B for prophylaxis of invasive fungal infection after graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: A comparative retrospective single-center study

Hematology/ Oncology and Stem Cell Therapy

Volumn 3, Issue 4, 2010, Pages 167-173

  El Cheikh, Jean ^a   Castagna, Luca ^a   Wang, Ling ^a   Esterni, Benjamin ^a   Faucher, Catherine ^a   Furst, Sabine ^a   Duran, Segolene ^a   Berger, Pierre ^a   Ranque, Stephane ^a   Mohty, Mohamad ^a   Blaise, Didier ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMIKACIN; AMOXICILLIN; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; COTRIMOXAZOLE; CYCLOSPORIN A; FLUCONAZOLE; GANCICLOVIR; ITRACONAZOLE; POSACONAZOLE; PREDNISONE; VALACICLOVIR; VANCOMYCIN; VORICONAZOLE; AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIINFLAMMATORY AGENT; PREDNISOLONE; BUSULFAN; FLUDARABINE; THYMOCYTE ANTIBODY;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX; HUMAN; INFECTION PREVENTION; INFECTION RATE; LIPOSOMAL DELIVERY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEPHROTOXICITY; PNEUMOCYSTIS PNEUMONIA; RETROSPECTIVE STUDY; SYSTEMIC MYCOSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; ALLOTRANSPLANTATION; COMPARATIVE STUDY; DRUG ADMINISTRATION; FUNGEMIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CAUSE OF DEATH; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; DRUG TOLERABILITY; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; INCIDENCE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; SOLID TUMOR; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; AMPHOTERICIN B; ANTI-INFLAMMATORY AGENTS; ANTIFUNGAL AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FUNGEMIA; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PREDNISOLONE; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 79952010280     PISSN: 16583876     EISSN: None     Source Type: Journal    
DOI: 10.5144/1658-3876.2010.167     Document Type: Article

References (26)

1. Mohty M, Bay JO, Faucher C, Choufi B, Bilger K, Tournilhac O, et al. Graft-versus-host disease folllowing allogeneic transplantation from HLA-identtical sibling with antithymocyte globulin-based redduced-intensity preparative regimen. Blood 2003; 102: 470-476.
2. Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, et al. Prospective survveillance for invasive fungal infections in hematoppoietic stem cell transplant recipients, 2001-2006: overview of the Transplant Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010 Apr 15; 50 (8):1091-100.
3. Jantunen E, Ruutu P, Niskanen L, Volin L, Parkkkali T, Koukila-Kähkölä P, Ruutu T. Incidence and risk factors for invasive fungal infections in alloggeneic BMT recipients. Bone Marrow Transplant 1997; 19: 801-808.
4. Martino R, Subirá M, Rovira M, Solano C, Vázquez L, Sanz GF, Urbano-Ispizua A, Brunet S, De la Cámmara R. Allo PBSCT Infectious/Non-infectious Compplications Subcommittees of the Grupo Español de Trasplante Hematopoyético (GETH). Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002; 116: 475-482.
5. Mohty M, Jacot W, Faucher C, Bay JO, Zandotti C, Collet L, et al. Infectious complications following alllogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia 2003; 17: 2168-2177.
6. Fukuda T, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG, Martin PJ, Storb RF, Marr KA. Risks and outcomes of invasive fungal infecttions in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative condditioning. Blood 2003; 102: 827-833.
7. Menichetti F, Del Favero A, Martino P, Bucaneve G, Micozzi A, Girmenia C, Barbabietola G, Pagao L, Leoni P, Specchia G, Caiozzo A, Raimondi R, Mandelli F. Itraconazole oral solution as prophyllaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. Clin Infect Dis 1999; 28: 250-255.
8. Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL, Leitz GJ, Terrrito MC. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randdomized trial. Ann Intern Med 2003; 138: 705-713.
9. Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA, Nichols WG, Musher B, Corey L. Itraconazole versus fluconazole for prevvention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103: 1527-1533.
10. Ullmann AJ, Lipton JH, Vesole DH, Chanddrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, Pediccone L, Patino H, Durrant S. Posaconazole or fluconnazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007 Jan 25; 356(4):335-47.
11. Stam WB, O'Sullivan AK, Rijnders B, Lugtenburg E, Span LF, Janssen JJ, Jansen JP. Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands. Eur J Haematol. 2008 Dec; 81(6):467-74.
12. Bodey GP, Anaissie EJ, Elting LS, Estey E, O'Brien S, Kantarjian H. Antifungal prophylaxis during remission induction therapy for acute leukkemia fluconazole versus intravenous amphotericcin B. Cancer 1994; 73: 2099-2106.
13. Herbrecht R, Denning DW, Patterson TF, Bennnett JE, Greene RE, Oestmann JW, et al. Invasive Fungal Infections Group of the European Organisattion for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole verssus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
14. Walsh TJ, Goodman JL, Pappas P, Bekersky I, Buell DN, Roden M, Barrett J, Anaissie EJ. Safety, tolerance, and pharmacokinetics of high-dose lipposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001; 45: 3487-3496.
15. Bekersky I, Boswell GW, Hiles R, Fielding RM, Buell D, Walsh TJ. Safety and toxicokinetics of inttravenous liposomal amphotericin B (AmBisome) in beagle dogs. Pharm Res 1999; 16: 1694-1701.
16. Bekersky I, Boswell GW, Hiles R, Fielding RM, Buell D, Walsh TJ. Safety, toxicokinetics and tisssue distribution of long-term intravenous liposommal amphotericin B (AmBisome): a 91-day study in rats. Pharm Res 2000; 17: 1494-1502.
17. Lee JW, Amantea MA, Francis PA, Navarro EE, Bacher J, Pizzo PA, Walsh TJ. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimiccrob Agents Chemother 1994; 38: 713-718.
18. Boswell GW, Bekersky I, Buell D, Hiles R, Walsh TJ. Toxicological profile and pharmacokinnetics of a unilamellar liposomal vesicle formulattion of amphotericin B in rats. Antimicrob Agents Chemother 1998; 42: 263-268.
19. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D et al. Liposomal ampphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Instittute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340: 764-771.
20. Tollemar J, Höckerstedt K, Ericzon BG, Sunddberg B, Ringdén O. Fungal prophylaxis with AmBisome in liver and bone marrow transplant recipients: results of two randomized double-blind studies. Transplant Proc 1994; 26:1833.
21. Cordonnier C, Mohty M, Faucher C, Pautas C, Robin M, Vey N, Monchecourt F, Mahi L, Ribaud P. Safety of a weekly high dose of liposomal ampphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PRPROPPHYSOME Study. Int J Antimicrob Agents 2008; 31: 135-141.
22. El-Cheikh J, Faucher C, Fürst S, Duran S, Bergeer P, Vey N, Stoppa AM, Bouabdallah R, Gastaut JA, Viens P, Blaise D, Mohty M. High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning alloggeneic stem cell transplantation. Bone Marrow Transplant 2007; 39: 301-306.
23. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Pattterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE; Eurropean Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Funggal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycosses Study Group (EORTC/MSG) Consensus Group; Clin Infect Dis 2008 Jun 15; 46: 1813-1821.
24. Penack O, Schwartz S, Martus P, Reinwald M, Schmidt-Hieber M, Thiel E, Blau IW. Low-dose liposomal amphotericin B in the prevention of invvasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann Oncol 2006; 17: 1306-1312.
25. Moen MD, Lyseng-Williamson KA, Scott LJ. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs 2009; 69: 361-392.
26. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleeslag D, Shah PM, Stevens DA, Walsh TJ; Invasive Fungal Infections Cooperative Group of the Europpean Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Definiing opportunistic invasive fungal infections in immmunocompromised patients with cancer and hemmatopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34(1): 7-14.